Pembrolizumab has been approved for multiple cancer types [19, 20] and was first approved by the FDA in 2017 for patients with previously treated GC, especially those with PD-L1-positive tumors (CPS ≥ 1) [21, 22]. The gene discussed is CD274; the disease is cancer.